Home / World News / GSK buys 10% stake of German biotech firm CureVac in $164-million deal

GSK buys 10% stake of German biotech firm CureVac in $164-million deal

GSK and CureVac, backed by Bill Gates, will work on developing up to five so-called mRNA-based vaccines and monoclonal antibodies (mAbs) for infectious diseases, they said.

Premium

For GSK, the world’s biggest vaccine maker, it adds to the company’s raft of investments in technologies that may fight future outbreaks.

Pushkala Aripaka & Arno Schuetze | Reuters

2 min read Last Updated : Jul 20 2020 | 10:22 PM IST

GSK will buy a 10 per cent stake in German biotech firm CureVac for £130 million ($163.67 million), the two firms said on Monday. This deal bets on new technologies already being used in potential Covid-19 vaccines.

GSK and CureVac, backed by Bill Gates, will work on developing up to five so-called mRNA-based vaccines and monoclonal antibodies (mAbs) for infectious diseases, they said. The deal points to a valuation of more than $1.6 billion for CureVac as it prepares for a stock market launch this year.

For GSK, the world’s biggest vaccine maker, it adds to the company’s raft of investments in

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in